Immunotech Laboratories BG

Immunotech Laboratories BG is a biotechnology company based in Bulgaria that specializes in the development of novel immunotherapies for chronic infectious diseases. The company's primary focus is the clinical advancement of Irreversible Pepsin Fraction (IPF), a proprietary therapeutic platform designed to treat HIV/AIDS and Hepatitis C. Its lead product candidate, ITL-101, has undergone Phase 1 and Phase 2 clinical trials in Bulgaria, demonstrating potential in reducing viral loads and improving immune response. The technology works by targeting viral envelope proteins to prevent cellular entry and viral replication. Immunotech Laboratories BG operates as a subsidiary of the U.S.-based Immunotech Laboratories, Inc., managing the European clinical and regulatory activities for their pipeline. The company aims to provide cost-effective alternative treatments for patients who are resistant to standard antiretroviral therapies.